These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19911440)

  • 21. Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression.
    Von Korff M; Katon W; Bush T; Lin EH; Simon GE; Saunders K; Ludman E; Walker E; Unutzer J
    Psychosom Med; 1998; 60(2):143-9. PubMed ID: 9560861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anxiety disorders, major depressive disorder and the dynamic relationship between these conditions: treatment patterns and cost analysis.
    François C; Despiégel N; Maman K; Saragoussi D; Auquier P
    J Med Econ; 2010 Mar; 13(1):99-109. PubMed ID: 20078336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment.
    Revicki DA; Simon GE; Chan K; Katon W; Heiligenstein J
    J Fam Pract; 1998 Dec; 47(6):446-52. PubMed ID: 9866670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoeconomic issues in the treatment of depression.
    Cohen LJ
    Formulary; 1995 Sep; 30 Suppl 1():S20-5. PubMed ID: 10151739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand.
    Prukkanone B; Vos T; Bertram M; Lim S
    Value Health; 2012; 15(1 Suppl):S3-8. PubMed ID: 22265064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant occupational therapy for work-related major depression works: randomized trial including economic evaluation.
    Schene AH; Koeter MW; Kikkert MJ; Swinkels JA; McCrone P
    Psychol Med; 2007 Mar; 37(3):351-62. PubMed ID: 17112401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does antidepressant step therapy fuel the law of unintended consequences?
    Greden JF
    Am J Psychiatry; 2010 Oct; 167(10):1148-51. PubMed ID: 20889657
    [No Abstract]   [Full Text] [Related]  

  • 30. The cost consequences of treatment-resistant depression.
    Russell JM; Hawkins K; Ozminkowski RJ; Orsini L; Crown WH; Kennedy S; Finkelstein S; Berndt E; Rush AJ
    J Clin Psychiatry; 2004 Mar; 65(3):341-7. PubMed ID: 15096073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression.
    Dobson KS; Hollon SD; Dimidjian S; Schmaling KB; Kohlenberg RJ; Gallop RJ; Rizvi SL; Gollan JK; Dunner DL; Jacobson NS
    J Consult Clin Psychol; 2008 Jun; 76(3):468-77. PubMed ID: 18540740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost of depression: effect of adherence and treatment response.
    von Knorring L; Akerblad AC; Bengtsson F; Carlsson A; Ekselius L
    Eur Psychiatry; 2006 Sep; 21(6):349-54. PubMed ID: 16777385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.
    Fava M; Rush AJ; Trivedi MH; Nierenberg AA; Thase ME; Sackeim HA; Quitkin FM; Wisniewski S; Lavori PW; Rosenbaum JF; Kupfer DJ
    Psychiatr Clin North Am; 2003 Jun; 26(2):457-94, x. PubMed ID: 12778843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the economic impact of screening and treatment for depression in the workplace.
    Evans-Lacko S; Koeser L; Knapp M; Longhitano C; Zohar J; Kuhn K
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):1004-13. PubMed ID: 27085517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costs of treating depression with individual versus family therapy.
    Crane DR; Christenson JD; Dobbs SM; Schaalje GB; Moore AM; Pedal FF; Ballard J; Marshall ES
    J Marital Fam Ther; 2013 Oct; 39(4):457-69. PubMed ID: 25800422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs and quality in the treatment of acute depression in primary care: a comparison between England, Germany and Switzerland.
    Gandjour A; Telzerow A; Lauterbach KW;
    Int Clin Psychopharmacol; 2004 Jul; 19(4):201-8. PubMed ID: 15201566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of the costs associated with depression and treatment noncompliance: the potential benefits of online support.
    Wade AG; Häring J
    Int Clin Psychopharmacol; 2010 Sep; 25(5):288-96. PubMed ID: 20715299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. S-Adenosyl Methionine (SAMe) for Depression in Adults.
    Wilson A
    Issues Ment Health Nurs; 2019 Aug; 40(8):725-726. PubMed ID: 30633610
    [No Abstract]   [Full Text] [Related]  

  • 39. Exact method for computing absolute percent change in a dichotomous outcome from meta-analytic effect size: improving impact and cost-outcome estimates.
    Miller TR; Hendrie D; Derzon J
    Value Health; 2011 Jan; 14(1):144-51. PubMed ID: 21211496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using elicitation techniques to estimate the value of ambulatory treatments for major depression.
    Normand SL; Frank RG; McGuire TG
    Med Decis Making; 2002; 22(3):245-61. PubMed ID: 12058782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.